Table 2. Overview of the IC50-values and CI obtained after sequential combination treatment for which CDDP was followed by Nutlin-3 in the p53 wild type cell lines A549 and A549-NTC, the p53 deficient cell line A549-920 and p53 mutant cell line CRL-5908.
| The role of p53 on cytotoxicity and synergism | ||||||
|---|---|---|---|---|---|---|
| Cell line | Nutlin-3 (μM) | CDDP (0-20 μM) | ||||
| IC50 | StDev | p-value* | CI | StDev | ||
| A549 | 0 | 5.51 | 0.66 | / | / | / |
| −> 5 μM | 2.67 | 0.26 | 0.003 | 0.486 | 0.138 | |
| A549-NTC | 0 | 4.63 | 0.35 | / | / | / |
| −> 5 μM | 3.69 | 0.27 | 0.024 | 0.785 | 0.370 | |
| A549-920 | 0 | 8.72 | 0.86 | / | / | / |
| −> 5 μM | 9.23 | 1.91 | 0.421 | 1.906 | 2.147 | |
| CRL-5908 | 0 | 9.60 | 0.63 | / | / | / |
| −> 5 μM | 9.70 | 1.73 | 0.700 | 1.453 | 0.447 | |
The average combination index (CI) is provided for each combination therapy. CI > 1 indicates an antagonistic effect, CI = 1 an additive effect and CI < 1 a synergistic effect.
*
(p < 0.05: significant difference in IC50-value compared to CDDP monotherapy)